Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies after reporting positive Phase 1 clinical results. The company announced that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting progression to Phase 2 trials.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, a key regulatory step that paves the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The therapy is designed to target demyelination and protect or restore myelin integrity, offering a potentially first-in-class approach that directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation.
The company is strengthening operational support for the program through a planned partnership with Allucent and by engaging neurological specialists. Quantum BioPharma believes LUCID-MS may provide a differentiated treatment option for multiple sclerosis, a chronic autoimmune disease affecting the central nervous system.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma focuses on research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The company also holds a 19.84% stake in Unbuzzd Wellness Inc. (UWI), which markets the OTC product unbuzzd™, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of rights to develop similar products for pharmaceutical and medical uses.
For investors, the advancement of LUCID-MS into Phase 2 trials represents a significant milestone for Quantum BioPharma. Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments often focus on immune modulation rather than directly repairing myelin damage. If successful, LUCID-MS could address an unmet medical need and provide a novel therapeutic option. The company’s progress also highlights its broader pipeline targeting neurodegenerative and metabolic disorders and alcohol misuse. More information is available in the company’s newsroom at https://ibn.fm/QNTM.
